Clinical Trial Update: Safety Study of RPE65 Gene Therapy to Treat Leber Congenital Amaurosis [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 safety study of RPE65 gene therapy for Leber congenital amaurosis has completed, according to the trial update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leber Congenital Amaurosis
• Retinal Degeneration

Drugs mentioned

• Luxturna (voretigene neparvovec-rzyl)

Snippet

Sponsor: University College, London | Conditions: Retinal Degeneration | Phase 1, Phase 2 | Status: COMPLETED